View Post

Less Chemotherapy, Fewer Falls, Personalized Care: Study Reinforces Major Strides in Geriatric Oncology

In In The News by Barbara Jacoby

From: PR Newswire Doctors can safely lower the dose of cancer treatment such as chemotherapy without impacting survival for adults older than 70 who are at high risk for toxic side effects. The results are from a potentially practice-changing new study, published in The Lancet, and led by a Wilmot Cancer Institute scientist at the University of Rochester Medical Center. …

View Post

Gilead, Merck to study combination therapy for breast cancer

In In The News by Barbara Jacoby

By: PBR Staff Writer From: pharmaceutical-business-review.com Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC). Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients …

View Post

Elacestrant extends PFS in advanced breast cancer

In In The News by Barbara Jacoby

From: healio.com A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer. Results showed the agent extended PFS compared with investigator’s choice of hormonal agent in the overall study population and the subgroup of those with estrogen receptor 1 (ESR1) …

View Post

Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: precisiononcologynews.com Veru, a Miami-based cancer drugmaker, on Wednesday said it has begun enrolling previously treated hormone receptor (HR)-positive, HER2-negative metastatic breast cancer patients in a Phase III trial of its anti-androgen receptor therapy enobosarm. The registration-directed trial, dubbed ARTEST, is specifically exploring the activity of enobosarm in advanced breast cancer patients with androgen receptor (AR)-positive and estrogen receptor (ER)-positive …

View Post

USC Opens Phase II Trial of Ambrx’s ARX788 for HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: precisiononcologynews.com The University of Southern California’s Norris Comprehensive Cancer Center on Monday said it has opened a Phase II trial of Ambrx’s antibody-drug conjugate ARX788 for advanced HER2-positive breast cancer patients. The trial, which is sponsored by La Jolla, California-based Ambrx, will involve roughly 200 HER2-positive metastatic breast cancer patients who have previously received trastuzumab emtansine (Genentech’s Kadcyla; T-DM1), …

View Post

Team discovers novel strategy to tame aggressive breast cancer and starts clinical trial

In Clinical Studies News by Barbara Jacoby

By: National Cancer Centre Singapore From: medicalxpress.com A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less …

View Post

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

From: prnewswire.com Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in …

View Post

Defence Therapeutics embark on next stage of breast cancer treatment development

In Clinical Studies News by Barbara Jacoby

From: healtheuropa.eu In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase 1 trial for its innovative AccuTOX breast cancer treatment. AccuTOX is one of Defence Therapeutics‘ premier candidates for effective breast cancer treatment and is comprised of the company’s cutting-edge AccumTM technology platform, which was …

View Post

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

In Clinical Studies News by Barbara Jacoby

Source: Inbiomotion From: prnewswire.com – Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis – Data published in Journal of National Cancer Institute, Cancer Spectrum – MAF-negative status of patients who were …

View Post

Radionuclide therapy a promising option to treat HER2 breast cancer

In Clinical Studies News by Barbara Jacoby

From: europeanpharmaceuticalreview.com The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen. A Phase I trial has found that radionuclide treatment may offer new therapeutic options for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The treatment combines radioactive iodine therapy with single-domain antibodies that target the HER2 antigen to destroy cancer cells. …